Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis
- 1 October 1990
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 117 (4), 556-560
- https://doi.org/10.1016/s0022-3476(05)80688-2
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysisThe Journal of Pediatrics, 1989
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989
- BLEEDING IN RENAL FAILUREThe Lancet, 1988
- Brainstem Auditory Evoked Potentials (BAEPs) in Childhood MigraineHeadache: The Journal of Head and Face Pain, 1988
- Recombinant Human Erythropoietin: Implications for NephrologyAmerican Journal of Kidney Diseases, 1988
- Pathogenesis of Cerebral Atrophy in UraemiaNephron, 1988
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- A comparison of gas exchange indices used to detect the anaerobic thresholdJournal of Applied Physiology, 1982
- CARDIOVASCULAR IMPAIRMENT AND PHYSICAL WORKING CAPACITY IN CHILDREN WITH CHRONIC RENAL FAILURE1Acta Paediatrica, 1978